BREAST CANCER

Register Now

Scoring & Interpretation

+The New Equivocal Changes to HER2 FISH Results When Applying the 2013 ASCO/CAP Guidelines

The New Equivocal Changes to HER2 FISH Results When Applying the 2013 ASCO/CAP Guidelines

Thomas H. Long et al.

This article focuses on the equivocal threshold established by the revised American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines to address HER2 status. Note: ASCP Membership is required to login and review this resource.
Register now to review full resource. Or, if you have registered, login now.

+Optimal Scoring of Brightfield Dual-Color In Situ Hybridization for Evaluation of HER2 Amplification in Breast Carcinoma How Many Cells Are Enough?

Optimal Scoring of Brightfield Dual-Color In Situ Hybridization for Evaluation of HER2 Amplification in Breast Carcinoma How Many Cells Are Enough?

Susan Prendeville MB, FRCPath et al.

This article reviews a study to determine the optimum number of cells that should be counted when scoring human epidermal growth factor receptor 2 (HER2) brightfield dual-color in situ hybridization (BDISH), including cases with HER2/chromosome 17 (Chr17) ratios in the 1.80 to 2.20 range. Note: ASCP Membership is required to login and review this resource.
Register now to review full resource. Or, if you have registered, login now.

+Nuclear Grade Plus Proliferation Grading System for Invasive Ductal Carcinoma of the Breast Validation in a Tertiary Referral Hospital Cohort

Nuclear Grade Plus Proliferation Grading System for Invasive Ductal Carcinoma of the Breast Validation in a Tertiary Referral Hospital Cohort

Maria Papadimitriou MD et al.

For patients with invasive breast cancer, management decisions are informed by tumor grade according to the Nottingham Grading System (NGS), either on its own or as part of the Nottingham Prognostic Index (NPI). A system retaining the nuclear grade element but substituting the two subjective components, mitosis count and tubule formation, of the NGS with a proliferation index based on Ki-67 (MIB-1) has been proposed (nuclear grade plus proliferation [N+P] grading). Note: ASCP Membership is required to login and review this resource.
Register now to review full resource. Or, if you have registered, login now.

+Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy.

Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy.

Peintinger F, Sinn B, Hatzis C, et al

Residual cancer burden assessment is highly reproducible with long term prognostic significance.
Register now to review full resource. Or, if you have registered, login now.

+Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines; Journal of Clinical Oncology July 25, 2016

Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines; Journal of Clinical Oncology July 25, 2016

Mithun Vinod Shah, Anne E. Wiktor, Reid G. Meyer, Kathleen S. Tenner, Karla V. Ballman, Stefan J. Green, William R. Sukov, Rhett P. Ketterling, Edith A. Perez, and Robert B. Jenkins

This article references a laboratory cohort that compares the HER2 FISH amplification using three guidelines.
Register now to review full resource. Or, if you have registered, login now.

+Immunohistochemical Markers

Immunohistochemical Markers

Rohit Bhargava, M.D.

This multimedia course discusses clinical, morphologic, immunohistochemical and genomic markers of breast cancer, lists universally accepted IHC markers, describes how hormone results are affects by pre-analytic, analytic, and post-analytic factors, describes the requirements for reliable hormone receptor testing, describes the Allred score and the ER and PR IHC scores. Note: ASCP Membership is required to login and review this resource.
Register now to review full resource. Or, if you have registered, login now.

+HER2 Targeted Therapy

HER2 Targeted Therapy

Rohit Bhargava, M.D.

This multimedia course will describe FDA approved methods of HER2 testing, HER2 immunohistochemistry, HER2 + score, ASO/CAP updated guidelines, HER2 re-testing, discuss whether polysomy is the new equivocal in HER2 testing, describe the type and pattern of HER2 heterogenity, identify HER2 positive and negative from a diagnostic image, and identify FISH in an IHC negative region from a diagnostic image. Note: ASCP Membership is required to login and review this resource.
Register now to review full resource. Or, if you have registered, login now.

+In-Situ Hybridization Assays

In-Situ Hybridization Assays

Rohit Bhargava, M.D.

This multimedia course describes the characteristics of chromogenic (CISH), Silver ISH (SISH), and Dual ISH (DISH). It also describes the characteristics of Bright Field In-Situ Hybridization (BrISH), discuses a research study that compared Bright-Field HER2 DISH vs. FISH, and compares the immunohistochemistry, FISH and CISH/SISH/DISH.
Register now to review full resource. Or, if you have registered, login now.

+HER2 Gene Protein Assay (IHC + DISH)

HER2 Gene Protein Assay (IHC + DISH)

Rohit Bhargava, M.D.

This multimedia course describes gene protein assay (IHC and DISH), discusses gene protein assay detection and identifies examples of GPA on an IHC from a diagnostic image. Note: ASCP Membership is required to login and review this resource.
Register now to review full resource. Or, if you have registered, login now.

+RT- PCR Assays

RT- PCR Assays

Rohit Bhargava, M.D.

This multimedia course describes the quantitative RT-PCR assays for HER2 and describes a quality assurance study comparing qRT-PCR for HER2 component ofoncotype DX®(ODX) test to a routine IHC/FISH approach. Note: ASCP Membership is required to login and review this resource.
Register now to review full resource. Or, if you have registered, login now.

+HER2 Testing Conclusions

HER2 Testing Conclusions

Rohit Bhargava, M.D.

This multimedia course discusses best practices for HER2 testing, describes the characteristics of Ki-67 immunohistochemistry, describes the clinical use of Ki-67 immunohistochemistry, and identifies the Ki-67 impact from a diagnostic image.
Register now to review full resource. Or, if you have registered, login now.

Systemic Treatment of Cancer

Rohit Bhargava, M.D.

This multimedia course discusses how genomic assays are used for breast cancer prognosis and treatment, discusses how multigene assays are used, describes and estimates Oncotype DX recurrence score, describes the design to build prediction models, describes the new Magee equation and compares the scores of Oncotype DX vs. Magee equations. Note: ASCP Membership is required to login and review this resource.
Register now to review full resource. Or, if you have registered, login now.

+Encapsulated Papillary Carcinoma

Encapsulated Papillary Carcinoma

Alessandro Bombonati, MD

This multimedia mini course describes characteristics of encapsulated papillary carcinoma, determines if encapsulated papillary carcinoma is in-situ or invasive, describes a course of action if there is no evidence of unequivocal invasive carcinoma, recognizing invasive papillary carcinoma from a diagnostic image, recognizing a blunt invasion encapsulated papillary carcinoma from a diagnostic image and describing the genomic landscape of papillary carcinomas.
Register now to review full resource. Or, if you have registered, login now.

+Solid Papillary Carcinoma

Solid Papillary Carcinoma

Alessandro Bombonati, MD

This multimedia mini course describes characteristics of solid papillary carcinoma, recognizes solid papillary carcinoma in-situ, solid papillary carcinoma with invasion, solid papillary carcinoma with blunt invasion, and molecular features of solid papillary carcinomas.
Register now to review full resource. Or, if you have registered, login now.

+Straightforward Papillomas

Straightforward Papillomas

Alessandro Bombonati, MD

This multimedia mini course recognizes a papilloma with high-grade DCIS from a diagnostic image, recognizes a papilloma with aprocrine DCIS from a diagnostic image, and recognizes an intraductal papillary carcinoma from a diagnostic image.
Register now to review full resource. Or, if you have registered, login now.

+Atypical Papillomas

Atypical Papillomas

Alessandro Bombonati, MD

This multimedia mini course discusses the size and histological features criteria for atypical papilloma, recognizes examples of atypical papilloma from diagnostic images, calculates an atypical papilloma diagnosis, describes the significance of ADH or DCIS in the surrounding breast tissue and recognizes the papilloma with high-grade DCIS from a diagnostic image.
Register now to review full resource. Or, if you have registered, login now.

+Papilloma Complications

Papilloma Complications

Alessandro Bombonati, MD

This multimedia mini course recognizes papilloma complications from sclerosis and entrapped cell clusters, recognizes papilloma complications from epithelial proliferations, lists the characteristics of papilloma with usual duct hyperplasia, recognizes papilloma with UDH: IHC from a diagnostic image, and describes the molecular features of papilloma.
Register now to review full resource. Or, if you have registered, login now.

+Papillary Lesions

Papillary Lesions

Alessandro Bombonati, MD

This multimedia mini course describes the characteristics of papillary lesions, central papilloma, and characteristics of peripheral papilloma.
Register now to review full resource. Or, if you have registered, login now.

This website is sponsored by:

 Founding Sponsor

Copyright © 2017. The American Society for Clinical Pathology. All rights reserved.